Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

NCT05300048 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Program prioritization

Conditions

Advanced Solid Tumor
PIK3CA Mutation
PTEN Loss of Function Mutation

Interventions

DRUG: Serabelisib
OTHER: Insulin Suppressing Diet
DRUG: Nab paclitaxel

Sponsor

Faeth Therapeutics